Oliver Schilling

Current Position

Heisenberg Professor for Translational Proteomics

Academic Education

1994 - 2000

Studies in Biology in Münster, Germany, and Tours, France (Diplom-Biologe and Licence de Biochimie)

Advanced Qualifications

2014	Habilitation (Venia Legendi) in Molecular Medicine, University of Freiburg
2004	Dissertation (Dr. rer. nat.), University of Münster

Postgraduate Positions

2018 - present	Heisenberg Professor for Translational Proteome Research at the Institute for Surgical Pathology, Medical Center - University of Freiburg
2008 - 2018	Research Group Leader, Institute of Molecular Medicine and Cell Research, University of Freiburg
2005 - 2008	Postdoctoral Fellow with Prof. Christopher M. Overall, University of British Columbia, Vancouver, CAN
2004	Postdoctoral Fellow, European Molecular Biology Laboratory, Outstation Hamburg
2000 - 2004	International PhD program, European Molecular Biology Laboratory, Outstation Hamburg

Link to all publications of Oliver Schilling: PubMed

Publications on CRC 1453 funding

Cosenza-Contreras M, Seredynska A, Vogele D, …, Huesgen PF, Kuehn EW, Kreutz C, Schell C, Schilling O. TermineR: Extracting information on endogenous proteolytic processing from shotgun proteomics data. Proteomics (2024). Fröhlich K, Fahrner M, Brombacher E, Seredynska A, Maldacker M, Kreutz C, Schmidt A, Schilling O. Data-independent acquisition: A milestone and prospect in clinical mass spectrometry-based proteomics. Mol Cell Proteomics (2024). Topitsch A, Halstenbach T, Rothweiler R, Fretwurst T, Nelson K, Schilling O. Mass Spectrometry-Based Proteomics of Poly(methylmethacrylate)-Embedded Bone. J Proteome Res (2024). Schneider J, Mitschke J, Bhat M, Vogele D, Schilling O, Reinheckel T, Heß L. Cathepsin D inhibition during neuronal differentiation selectively affects individual proteins instead of overall protein turnover. Biochimie (2024). Stillger MN, Kurowski K, Bronsert P, Brombacher E, Kreutz C, Werner M, Tang L, Timme Bronsert S, Schilling O. Neoadjuvant chemo- or chemo-radiation-therapy of pancreatic ductal adenocarcinoma differentially shift ECM composition, complement activation, energy metabolism and ribosomal proteins of the residual tumor mass. Int J Cancer (2024). Halstenbach T, Topitsch A, Schilling O, Iglhaut G, Nelson K, Fretwurst T. Mass spectrometry-based proteomic applications in dental implants research. Proteomics Clin Appl (2024). Mehta S, Bernt M, Chambers M, Fahrner M, Föll MF, …, Schilling O, …, Price G, Jagtap PD, Griffin TJ. A Galaxy of informatics resources for MS-based proteomics. Expert Rev Proteomics (2023). Cosenza-Contreras M, Schäfer A, Sing J, Cook L, Stillger MN, …, Arnoux A, Bartsch JW, Schilling O. Proteometabolomics of initial and recurrent glioblastoma highlights an increased immune cell signature with altered lipid metabolism. Neuro Oncol (2023). Trevisan-Silva D, Cosenza-Contreras M, Oliveira UC, da Rós N, Andrade-Silva D, …, Nishiyama-Jr. MY, Schilling O, Serrano SMT. Systemic toxicity of snake venom metalloproteinases: Multi-omics analyses of kidney and blood plasma disturbances in a mouse model. Int J Biol Macrobiol (2023). Rogg M, Maier JI, Helmstädter M, Sammarco A, Kliewe F, …, Endlich N, Schilling O, Schell C. A YAP/TAZ-ARHGAP29-RhoA Signaling Axis Regulates Podocyte Protrusions and Integrin Adhesions. Cells (2023). Koistinen H, Kovanen RM, Hollenberg MD, Dufour A, Radisky ES, …, Schilling O, Rannikko A, Mirtti T. The roles of proteases in prostate cancer. IUBMB Life (2023). Siegel PM, Barta BA, Orlean L, Steenbuck ID, Cosenza-Contreras M, …, Westermann D, Schilling O, Diehl P. The serum proteome of VA-ECMO patients changes over time and allows differentiation of survivors and non-survivors: an observational study. J Transl Med (2023). Kocsmár E, Schmid M, Cosenza-Contreras M, Kocsmár I, Föll M, …, Schilling O, Lotz G, Bronsert P. Proteome alterations in human autopsy tissues in relation to time after death. Cell Mol Life Sci (2023). Stillger MN, Chen CY, Lai ZW, Li M, Schäfer A, Pagenstecher A, Nimsky C, Bartsch JW, Schilling O. Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis. Cancer Cell Int (2023). Werner J, Bernhard P, Cosenza-Contreras M, Pinter N, Fahrner M, …, Bronsert P, Rückert F, Schilling O. Targeted and explorative profiling of kallikrein proteases and global proteome biology of pancreatic ductal adenocarcinoma, chronic pancreatitis, and normal pancreas highlights disease-specific proteome remodelling. Neoplasia (2023). Halstenbach T, Nelson K, Iglhaut G, Schilling O, Fretwurst T. Impact of peri-implantitis on the proteome biology of crevicular fluid: A pilot study. J Periodontol (2022). Shahinian JH, Hauser-Stadler CB, Walter T, Discher P, Steenbuck ID, Schilling O, Czerny M. Acute, Chronic, and Treated Aortic Diseases Present Distinguishable Serum Proteome Fingerprints with Protein Profiles That Correlate with Disease Severity. Biomedicines (2022). Bernhard P, Bretthauer BA, Brixius SJ, Bügener H, Groh JE, …, Beyersdorf F, Schilling O, Pooth JS. Serum proteome alterations during conventional and extracorporeal resuscitation in pigs. J Transl Med (2022). Fröhlich K, Brombacher E, Fahrner M, Vogele D, Kook L, …, Bärenfaller K, Kreutz C, Schilling O. Benchmarking of analysis strategies for data-independent acquisition proteomics using a large-scale dataset comprising inter-patient heterogeneity. Nat Commun (2022). Pinter N, Glätzer D, Fahrner M, Fröhlich K, Johnson J, …, Drepper F, Schilling O, Föll MC. MaxQuant and MSstats in Galaxy Enable Reproducible Cloud-Based Analysis of Quantitative Proteomics Experiments for Everyone. J Proteome Res (2022). Rogg M, Maier JI, Ehle M, Sammarco A, Schilling O, Werner M, Schell C. NUP133 Controls Nuclear Pore Assembly, Transcriptome Composition, and Cytoskeleton Regulation in Podocytes. Cells (2022). Fahrner M, Föll MC, Grüning BA, Bernt M, Röst H, Schilling O. Democratizing data-independent acquisition proteomics analysis on public cloud infrastructures via the Galaxy framework. Gigascience (2022). Fayçal CA, Oszwald A, Feilen T, Cosenza-Contreras M, Schilling O, …, Rees AJ, Orend G, Kain R. An adapted passive model of anti-MPO dependent crescentic glomerulonephritis reveals matrix dysregulation and is amenable to modulation by CXCR4 inhibition. Matrix Biol (2022). Fahrner M, Bronsert P, Fichtner-Feigl S, Jud A, Schilling O. Proteome biology of primary colorectal carcinoma and corresponding liver metastases. Neoplasia (2021).